The company ended the quarter with cash totaling $7.6M, compared to $3.7M as of December 31, 2024. During the fourth quarter, the company raised a total of approximately $1.5M of gross proceeds through purchases under the Equity Line of Credit, with gross proceeds of purchases under the Equity Line of Credit totaling approximately $4M for the full year.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
- ACXP Earnings this Week: How Will it Perform?
- Acurx Advances Ibezapolstat Program for Recurrent C. difficile
- Acurx announces new ibezapolstat clinical trial program
- Acurx files to sell 750,000 shares of common stock for holders